Therefore, these findings suggested the hypothesis that TMZ might exert anti-tumor effects through MSH2/MSH6/TOP2B/XRCC3 in glioma patients via a regulated interaction with the TP53 signaling axis. The gene discussed is XRCC3; the disease is glioma.